Skip to main content
. Author manuscript; available in PMC: 2018 Jul 30.
Published in final edited form as: J Acquir Immune Defic Syndr. 2010 Sep;55(1):39–48. doi: 10.1097/QAI.0b013e3181da1287

FIGURE 1.

FIGURE 1

Subject accounting. A CONSORT diagram shows patient disposition through study week 96. A total of 3 randomized patients, including 1 patient in the raltegravir arm and 2 patients in the efavirenz arm, never received study drugs. For the calculation of percentages subsequent to entry, the number of treated patients in each group was assigned a value of 100%.